BROAD INSTITUTE and MD ANDERSON CANCER CENTER were designated the Genome Characterization Centers in a five-year project supported by the NCI to characterize the genomic changes found in tumors.
GCC’s funding comes via a research subcontract with Leidos Biomedical Research Inc., operations and technical support contractor for NCI’s Frederick National Laboratory for Cancer Research.
The centers will provide Whole Genome, Whole Exome and RNA sequencing to support three main project areas:
- The Exceptional Responders Initiative aimed at discovering and understanding the molecular events involved in extraordinary individual responses to otherwise unsuccessful targeted experimental cancer therapies.
- The ALCHEMIST Project (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) aimed at providing molecular data to support biomarker classification and genomic characterization of lung cancer patients enrolled in clinical trials.
- The Cancer Driver Discovery Project aimed at providing additional statistical power to discover driver mutations in lung, colon and ovarian cancer.
The project was funded under Contract No. HHSN261200800001E.
